Edition:
United States

GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

45.07USD
29 Jul 2016
Change (% chg)

$-0.11 (-0.24%)
Prev Close
$45.18
Open
$45.19
Day's High
$45.38
Day's Low
$44.85
Volume
2,978,330
Avg. Vol
3,472,671
52-wk High
$45.45
52-wk Low
$36.71

Latest Key Developments (Source: Significant Developments)

Vectura initiates legal proceedings against GSK in the U.S.
Wednesday, 27 Jul 2016 12:19pm EDT 

Vectura Group Plc : Vectura initiates legal proceedings against GlaxoSmithKline Plc (GSK) . Vectura has filed a patent infringement lawsuit against GSK claiming infringement of Vectura's U.S. patents in Delaware district court . Continues to remain open to finding a mutually acceptable solution in order to avoid costs and potential uncertainty over royalties that have, up to now, been subject to a cap of 13 mln stg per calendar year . Separate licence agreement with GSK relating to legacy Skyepharma dry powder formulation technology used in Ellipta products is unaffected .Despite notification from GSK, directors believe that revenues for current financial year ending December 2016 remain in line with current expectations.  Full Article

GSK CEO: UK competitive post-Brexit but questions over drug regulation, science
Wednesday, 27 Jul 2016 07:00am EDT 

GlaxoSmithKline CEO told reporters: Ceo says board looking at internal and external candidates to be new ceo, decision around end year . Ceo says sees reopening of conversations on drug pricing in europe and u.s. in 2017 . Ceo says sees evolution on drug pricing, changes to more outcomes-based models likely in 2018 and 2019 . Ceo says fundamental competitiveness of uk remains exactly the same as before brexit vote . Ceo says q2 tends to be weaker quarter for consumer business, still expects margin to get to 20 percent mid term . Ceo says expectation is that EMA will move from london, "somewhat concerned" that may bring disruption . Ceo says risk of scientific brain drain post-brexit is "question-mark we should all be concerned about" Further company coverage: [GSK.L] (Reporting by UK bureau) ((uk.online@reuters.com;)).  Full Article

GlaxoSmithKline ships 2016-17 seasonal influenza vaccines for US market
Wednesday, 20 Jul 2016 03:51pm EDT 

GlaxoSmithKline Plc : GSK ships 2016-17 seasonal influenza vaccines for US market .Expects to supply up to 40 million doses across both vaccines for US market in 2016-17 season.  Full Article

ARIA study shows superior efficacy of Triumeq for treatment-naïve women with HIV
Monday, 18 Jul 2016 06:16am EDT 

Viiv Healthcare: ARIA study shows superior efficacy of Triumeq for treatment-naïve women living with HIV .Both non-inferiority and superiority endpoints were met.  Full Article

Mylan launches generic version of GSK's avodart capsules
Friday, 24 Jun 2016 11:44am EDT 

Mylan NV: Mylan launches generic Avodart® capsules .U.S. launch of Dutasteride capsules, 0.5 mg, generic version of GlaxoSmithKline's avodart capsules.  Full Article

GlaxoSmithKline says lung drug meets late-stage study goals
Monday, 20 Jun 2016 02:02am EDT 

Glaxosmithkline Plc : Fulfil study results closed triple eu . Fulfil study shows superiority of closed triple combination therapy ff/umec/vi versus symbicort turbohaler . Data supports regulatory submission by gsk in europe by end of 2016 . Positive top-line results from phase iii study of fluticasone furoate/umeclidinium/vilanterol . Study met its two co-primary endpoints .Study demonstrated statistically significant improvements in lung function and health- related quality of life.  Full Article

GlaxoSmithKline says vaccines chairman Slaoui to retire in 2017
Tuesday, 14 Jun 2016 05:58am EDT 

Glaxosmithkline Plc : Moncef Slaoui, Chairman, Vaccines, has indicated to board his intention to retire from company in 2017 . Board supports Dr Slaoui's decision and has agreed he will retire on June 30 2017 .Slaoui will remain member of board until March 31 2017; from April 1 2017 until retirement will serve as an advisor to GSK.  Full Article

ViiV Healthcare says FDA approves sNDA for dolutegravir
Friday, 10 Jun 2016 09:10am EDT 

Viiv Healthcare Ltd : ViiV Healthcare announces FDA approval to lower weight limit for dolutegravir in children and adolescents living with HIV . FDA has approved a supplemental new drug application for dolutegravir 10mg and 25mg oral tablets, reducing weight limit . FDA approved supplemental new drug application for dolutegravir oral tablets, reducing weight limit to at least 30kg Further company coverage: [IPO-VIHL.L] (Bengaluru Newsroom: +91 80 6749 1136).  Full Article

GSK rheumatoid arthritis, SLE drug meets late stage study goal
Wednesday, 8 Jun 2016 05:38am EDT 

Glaxosmithkline Plc :New phase III data shows greater treatment response with GSK's Benlysta (Belimumab) versus placebo in patients with highly active SLE.  Full Article

Mylan launches generic rythmol sustained-release capsules
Thursday, 2 Jun 2016 07:00am EDT 

Mylan NV : Mylan launches generic rythmol sustained-release capsules .U.S. launch of propafenone hydrochloride extended-release capsules USP, 225 mg, 325 mg, 425 mg, a generic version of glaxosmithkline's Rythmol Sr.  Full Article

PRESS DIGEST- British Business - July 28

July 28 The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.